Xuguang (Sean) Li

E-Card

Xuguang (Sean) Li
Adjunct Professor, Research Scientist, Health Canada

MD, Medical College of Suzhou University
PhD, McGill University
Post-Doctoral Fellow, Dana Farber Cancer Institute, Harvard Medical School

Office: 613-954-2383
Fax: 613-941-8933
Work E-mail: sean.li@canada.ca
Work E-mail: SL3@uottawa.ca

Dr. Xuguang (Sean) Li

Biography

Research Interests:

Dr. Sean (Xuguang) Li received his medical degree in China, followed by a graduate study and research training in Beijing. He obtained his PhD in experimental medicine from McGill University. As a research fellow, he conducted cancer and virus research at Dana Farber Cancer Institute of Harvard Medical School before he joined the National Microbiology Laboratory in Canada. Currently, Dr. Li is a Senior Research Scientist heading the Vaccine Research Laboratory at Health Canada and an Adjunct Professor at the Department of Biochemistry, Microbiology and Immunology; he is also a member of Faculty of the Graduate and Postdoctoral Studies, University of Ottawa.

The following are highlights of his research activities:

  • Gene Therapy and Biotherapeutics: Targeted gene therapy and immunotherapy by viral vectors and molecular ligands
  • Molecular Studies of respiratory viruses virus (Influenza, RSV, SARS-CoV and MERS-CoV) in relation to replication and immunopathogenesis
  • Vaccine Research: Investigation of universal epitopes of respiratory viruses for the induction of broad and long lasting immune responses
  • Antibody Engineering: Selective generation of universal antibodies with high affinity to viral epitopes which are normally weak in immunogenicity

(Currently hiring graduate students)

Select publications since 2010 (out of a total 130+ publications)

  • Muralidharan A, Russell M, Larocque L, C Gravel, S Sauve, Z Chen, C Li, W Chen, T Cyr, M Rosu-Myles, L Wang, X. Li. Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice. 2019. Vaccine (In Press)
  • She YM, Li X, Cyr TD. Remarkable Structural Diversity of N-Glycan Sulfation on Influenza Vaccines. Anal Chem. 2019 Apr 16;91(8):5083-5090. (in press)
  • Russell MS, Creskey M, Muralidharan A, Li C, Gao J, Chen W, Larocque L, Lavoie JR, Farnsworth A, Rosu-Myles M, Hashem AM, Yauk CL, Cao J, Van Domselaar G, Cyr T, Li X. Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine. Front Immunol. 2019 Mar 29;10:597. doi: 10.3389/fimmu.2019.00597. eCollection 2019.
  • Hashem AM, Algaissi A, Agrawal A, Al-Amri SS, Alhabbab RY, Sohrab SS, Almasoud A, Alharbi NK, Peng BH, Russell M, Li X, K Tseng CT. A highly immunogenic, protective and safe adenovirus-based vaccine expressing MERS-CoV S1-CD40L fusion protein in transgenic human DPP4 mouse model. J Infect Dis. 2019 Mar 26. pii:jiz137. doi: 10.1093/infdis/jiz137. [Epub ahead of print]
  • Jiang Z, Liu G, Guo-Yang L, Sun M, Xu K, Ying Z, Wang J, Li X, Li C. A simple and safe antibody neutralization assay based on polio pseudoviruses. Hum Vaccin Immunother. 2019;15(2):349-357.
  • Ning T, Nie J, Huang W, Li C, Li X, Liu Q, Zhao H, Wang Y. Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin. J Infect Dis. 2019 Jan 1;219(1):19-25.
  • Zhao H, Xu K, Jiang Z, Shao M, Liu S, Li X, Wang J, Li C. A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines. PLoS One. 2018 Nov 15;13(11):e0207431.
  • Muralidharan A, Russell M, Larocque L, Gravel C, Li C, Chen W, Cyr T, Lavoie JR, Farnsworth A, Rosu-Myles M, Wang L, Li X. Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection. Sci Rep. 2018 Nov 9;8(1):16648.
  • Russell MS, Muralidharan A, Larocque L, Cao J, Deschambault Y, Varga J, Thulasi Raman SN, Li X. Identification and characterisation of the CD40-ligand of Sigmodon hispidus. PLoS One. 2018 Jul 27;13(7):e0199067.
  • Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Liu S, Xie Y, Gadde S, Li X, Wang L. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018 Jul 26;9(8):815.
  • Muralidharan A, Gravel C, Duran A, Larocque L, Li C, Zetner A, Van Domselaar G, Wang L, Li X. Identification of immunodominant CD8 epitope in the stalk domain of influenza B viral hemagglutinin. Biochem Biophys Res Commun. 2018 Jul 12;502(2):226-231.
  • Tian Y, Zhao H, Liu Q, Zhang C, Nie J, Huang W, Li C, Li X, Wang Y. Development of in vitro and in vivo neutralization assays based on the pseudotyped H7N9 virus. Sci Rep. 2018 May 31;8(1):8484.
  • Wang C, Zhou S, Xue W, Shen L, Huang W, Zhang Y, Li X, Wang J, Zhang H, Ma X. Comprehensive virome analysis reveals the complexity and diversity of the viral spectrum in pediatric patients diagnosed with severe and mild hand-foot-and-mouth disease. Virology. 2018 May;518:116-125.
  • Sulaiman A, McGarry S, Li L, Jia D, Ooi S, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Gadde S, Li X, Wang L. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Mol Oncol. 2018 Apr;12(4):423-440.
  • Xu K, Li C, Gravel C, Jiang Z, Jaentschke B, Van Domselaar G, Li X, Wang J. Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines. Sci Rep. 2018 Jan 18;8(1):1067.
  • Li Q, Liu Q, Huang W, Li X, Wang Y. Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018 Jan;28(1). doi:10.1002/rmv.1963..
  • Lorbetskie B, Fortin N, Durno L, Wang J, Li C, Li X, Girard M, Sauvé S. Fast and highly selective determination of hemagglutinin content in quadrivalent influenza vaccine by reversed-phase high-performance liquid chromatography method. J Chromatogr A. 2017 Dec 15;1528:18-24.
  • Peng B, Peng N, Zhang Y, Zhang F, Li X, Chang H, Fang F, Wang F, Lu F, Chen Z. Comparison of the Protective Efficacy of Neutralizing Epitopes of 2009 Pandemic H1N1 Influenza Hemagglutinin. Front Immunol. 2017 Aug 31;8:1070. PMCID: PMC5583165.
  • She YM, Farnsworth A, Li X, Cyr TD. Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines. Sci Rep. 2017 Aug 31;7(1):10232.
  • Jia D, Li L, Andrew S, Allan D, Li X, Lee J, Ji G, Yao Z, Gadde S, Figeys D, Wang L. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis. 2017 Jul 13;8(7):e2932.
  • Manceur AP, Zou W, Marcil A, Paquet E, Gadoury C, Jaentschke B, Li X, Petiot E, Durocher Y, Baardsnes J, Rosa-Calatrava M, Ansorge S, Kamen AA. Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza. PLoS One. 2017 Jun 29;12(6):e0180314.
  • Muralidharan A, Li C, Wang L, Li X. Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies. Expert Rev Vaccines. 2017 Apr;16(4):351-360.
  • Li Y, Fu Y, Liu X, Yang H, Yu Y, Jia L, Li X, Farnsworth A, Wang J. The molecular determinants governing the immunogenicity of Japanese encephalitis live attenuated vaccines. Signal Transduct Target Ther. 2017 Mar 24;2:17005.
  • Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, Alhabbab RY, Azhar EI, Li X, Hashem AM. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Sci Rep. 2017 Mar 23;7:44875.
  • Nie J, Wu X, Ma J, Cao S, Huang W, Liu Q, Li X, Li Y, Wang Y. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep. 2017 Feb 20;7:42769.
  • Sulaiman A, Sulaiman B, Khouri L, McGarry S, Nessim C, Arnaout A, Li X, Addison C, Dimitroulakos J, Wang L. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and Erα coinhibition. FEBS Lett. 2016 Dec;590(24):4606-4616.
  • Zheng M, Qu D, Wang H, Sun Z, Liu X, Chen J, Li C, Li X, Chen Z. Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model. Sci Rep. 2016 Jun 29;6:28729.
  • Venereo-Sanchez A, Gilbert R, Simoneau M, Caron A, Chahal P, Chen W, Ansorge S, Li X, Henry O, Kamen A. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. Vaccine. 2016 Jun 17;34(29):3371-80.
  • Yu CF, Hou JF, Shen LZ, Gao K, Rao CM, Yang PY, Fu ZH, Wang QZ, Li YH, Wang L, Liu F, Zhang L, Qu Z, Shen Q, Li B, Li X, Wang JZ. Acute pulmonary embolism caused by highly aggregated intravenous immunoglobulin. Vox Sang. 2016 Jan;110(1):27-35.
  • Gravel C, Elmgren C, Muralidharan A, Hashem AM, Jaentschke B, Xu K, Widdison J, Arnold K, Farnsworth A, Rinfret A, Van Domselaar G, Wang J, Li C, Li X. Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines. Vaccine. 2015 Feb 25;33(9):1129-34.
  • Fan X, Hashem AM, Chen Z, Li C, Doyle T, Zhang Y, Yi Y, Farnsworth A, Xu K, Li Z, He R, Li X, Wang J. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. Mucosal Immunol. 2015 Jan;8(1):211-20.
  • Hashem AM, Gravel C, Chen Z, Yi Y, Tocchi M, Jaentschke B, Fan X, Li C, Rosu-Myles M, Pereboev A, He R, Wang J, Li X. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus. J Immunol. 2014 Jul 15;193(2):722-34.
  • She YM, Cheng K, Farnsworth A, Li X, Cyr TD. Surface modifications of influenza proteins upon virus inactivation by β-propiolactone. Proteomics. 2013 Dec;13(23-24):3537-47.
  • Doyle TM, Li C, Bucher DJ, Hashem AM, Van Domselaar G, Wang J, Farnsworth A, She YM, Cyr T, He R, Brown EG, Hurt AC, Li X. A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem Biophys Res Commun. 2013 Nov 8;441(1):226-9.
  • Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 2013 Nov;100(2):567-74.
  • Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 2013 Nov;100(2):567-74. doi: 10.1016/j.antiviral.2013.09.018. Epub 2013 Sep 30. PubMed PMID: 24091204.
  • Doyle TM, Jaentschke B, Van Domselaar G, Hashem AM, Farnsworth A, Forbes NE, Li C, Wang J, He R, Brown EG, Li X. The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication. J Biol Chem. 2013 Jun 21;288(25):18283-9.
  • Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A,  Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Sohn Y, Wood D. A global regulatory science agenda for vaccines. Vaccine. 2013 Apr 18;31 Suppl 2:B163-75. doi: 10.1016/j.vaccine.2012.10.117. Review. PubMed PMID: 23598478.
  • Hashem AM, Gravel C, Farnsworth A, Zou W, Lemieux M, Xu K, Li C, Wang J, Goneau MF, Merziotis M, He R, Gilbert M, Li X. A novel synthetic receptor-based immunoassay for influenza vaccine quantification. PLoS One. 2013;8(2):e55428.
  • Bliu A, Lemieux M, Li C, Li X, Wang J, Farnsworth A. Modifying the thermostability of inactivated influenza vaccines. Vaccine. 2012 Aug 10;30(37):5506-11.
  • Creskey MC, Li C, Wang J, Girard M, Lorbetskie B, Gravel C, Farnsworth A, Li X, Smith DG, Cyr TD. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Vaccine. 2012 Jul 6;30(32):4762-70.
  • Hashem A, Jaentschke B, Gravel C, Tocchi M, Doyle T, Rosu-Myles M, He R, Li X. Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge. Hum Vaccin Immunother. 2012 Apr;8(4):425-30.
  • Russell MS, Li C, Larocque L, Wang J, Farnsworth A, He R, Li X. Rapid and accurate determination of the potency of varicella vaccine by quantitative polymerase chain reaction. Vaccine. 2011 Nov 3;29(47):8490-5.
  • Johnston MJ, Frahm G, Li X, Durocher Y, Hefford MA. O-linked glycosylation leads to decreased thermal stability of interferon alpha 2b as measured by two orthogonal techniques. Pharm Res. 2011 Jul;28(7):1661-7.
  • Flaman AS, Gravel C, Hashem AM, Tocchi M, Li X. The effect of interferon-α on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol. 2011 Jun 1;253(2):130-6.
  • Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, Li X, Girard M.   Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine. 2011 Apr 18;29(18):3377-89.
  • Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Van Domselaar G, He R, Li X. Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays. J Vis Exp. 2011 Apr 4;(50). pii: 2784. doi: 10.3791/2784. PubMed PMID: 21490585;
  • Farnsworth A, Cyr TD, Li C, Wang J, Li X. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine. 2011 Feb 11;29(8):1529-33.
  • Larocque L, Bliu A, Xu R, Diress A, Wang J, Lin R, He R, Girard M, Li X. Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotechnol. 2011;2011:174615.
  • Hashem AM, Van Domselaar G, Li C, Wang J, She YM, Cyr TD, Sui J, He R, Marasco WA, Li X. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun. 2010 Dec 10;403(2):247-51.
  • Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu KW, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, Girard M, He R, Li X. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine. 2010 Aug 16;28(36):5774-84.
  • Farnsworth A, Flaman AS, Prasad SS, Gravel C, Williams A, Yauk CL, Li X. Acetaminophen modulates the transcriptional response to recombinant interferon-beta. PLoS One. 2010 Jun 9;5(6):e11031.
  • Diress A, Lorbetskie B, Larocque L, Li X, Alteen M, Isbrucker R, Girard M. Study of aggregation, denaturation and reduction of interferon alpha-2 products by size-exclusion high-performance liquid chromatography with fluorescence detection and biological assays. J Chromatogr A. 2010 May 7;1217(19):3297-306.
  • Chiang S, Burch T, Van Domselaar G, Dick K, Radziwon A, Brusnyk C, Edwards MR, Piper J, Cutts T, Cao J, Li X, He R. The interaction between thymine DNA glycosylase and nuclear receptor coactivator 3 is required for the transcriptional activation of nuclear hormone receptors. Mol Cell Biochem. 2010 Jan;333(1-2):221-32.
  • Li C, Jaentschke B, Song Y, Wang J, Cyr TD, Van Domselaar G, He R, Li X. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc. 2010 Jan;5(1):14-9. doi: 10.1038/nprot.2009.200

Fields of Interest

  • Immunopathogenesis of RNA virus infection
  • Viral vaccine and anti-viral therapy
  • Microbiology
Back to top